Achilles Therapeutics Company
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.
Investors
Connections from
Founded Date:
2016-05-01
Technology:
Medical BioTech
Funding Status:
IPO
Total Funding:
212991704.0
Employee Number:
1-10
Headquarters:
London, England, United Kingdom
Last Funding Date:
2022-07-21
Investors Number:
15.0
Last Funding Type:
Grant
Estimated Revenue:
$10M to $50M
Industry:
Medical BioTech